ZA201104469B - Carbazole carboxamide compounds useful as kinase inhibitors - Google Patents

Carbazole carboxamide compounds useful as kinase inhibitors

Info

Publication number
ZA201104469B
ZA201104469B ZA2011/04469A ZA201104469A ZA201104469B ZA 201104469 B ZA201104469 B ZA 201104469B ZA 2011/04469 A ZA2011/04469 A ZA 2011/04469A ZA 201104469 A ZA201104469 A ZA 201104469A ZA 201104469 B ZA201104469 B ZA 201104469B
Authority
ZA
South Africa
Prior art keywords
kinase inhibitors
compounds useful
carboxamide compounds
carbazole carboxamide
carbazole
Prior art date
Application number
ZA2011/04469A
Other languages
English (en)
Inventor
Qingjie Liu
George V Delucca
Andrew J Tebben
Douglas G Batt
Qing Shi
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of ZA201104469B publication Critical patent/ZA201104469B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA2011/04469A 2008-12-19 2011-06-15 Carbazole carboxamide compounds useful as kinase inhibitors ZA201104469B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13904708P 2008-12-19 2008-12-19
PCT/US2009/068415 WO2010080481A1 (en) 2008-12-19 2009-12-17 Carbazole carboxamide compounds useful as kinase inhibitors

Publications (1)

Publication Number Publication Date
ZA201104469B true ZA201104469B (en) 2012-11-28

Family

ID=41622163

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2011/04469A ZA201104469B (en) 2008-12-19 2011-06-15 Carbazole carboxamide compounds useful as kinase inhibitors

Country Status (22)

Country Link
US (2) US8084620B2 (enExample)
EP (1) EP2391602B1 (enExample)
JP (1) JP5487214B2 (enExample)
KR (1) KR20110098827A (enExample)
CN (1) CN102325753B (enExample)
AR (1) AR074812A1 (enExample)
AU (1) AU2009335821A1 (enExample)
BR (1) BRPI0922565A2 (enExample)
CA (1) CA2747670A1 (enExample)
CL (1) CL2011001516A1 (enExample)
CO (1) CO6390055A2 (enExample)
EA (1) EA019041B1 (enExample)
ES (1) ES2443948T3 (enExample)
IL (1) IL213185A0 (enExample)
MX (1) MX2011006171A (enExample)
NZ (1) NZ593096A (enExample)
PE (1) PE20110819A1 (enExample)
SG (1) SG171815A1 (enExample)
TN (1) TN2011000274A1 (enExample)
TW (1) TW201028401A (enExample)
WO (1) WO2010080481A1 (enExample)
ZA (1) ZA201104469B (enExample)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5682051B2 (ja) * 2006-05-18 2015-03-11 ファーマサイクリックス，インク． 細胞内キナーゼ阻害剤
JP5487214B2 (ja) * 2008-12-19 2014-05-07 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ阻害剤として有用なカルバゾールカルボキシアミド化合物
US8785440B2 (en) 2009-09-04 2014-07-22 Biogen Idec Ma, Inc. Bruton's tyrosine kinase inhibitors
US8685969B2 (en) 2010-06-16 2014-04-01 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
JP5674823B2 (ja) * 2011-01-25 2015-02-25 三井化学アグロ株式会社 芳香族アミドカルボン酸誘導体の製造方法
WO2012156334A1 (en) * 2011-05-17 2012-11-22 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
WO2013156431A1 (en) 2012-04-17 2013-10-24 Syngenta Participations Ag Pesticidally active pyridyl- and pyrimidyl- substituted thiazole and thiadiazole derivatives
WO2013157021A1 (en) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
CA2869954C (en) 2012-04-20 2023-01-03 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof in medical conditions related to modulation of bruton's tyrosine kinase activity
AR091273A1 (es) * 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
US9353087B2 (en) 2012-06-08 2016-05-31 Biogen Ma Inc. Inhibitors of Bruton's tyrosine kinase
BR112015001690A2 (pt) 2012-07-24 2017-11-07 Pharmacyclics Inc mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk)
US9447039B2 (en) * 2012-09-07 2016-09-20 Novartis Ag Indole carboxamide derivatives and uses thereof
CN104884458B (zh) 2013-04-25 2017-04-12 百济神州有限公司 作为蛋白质激酶抑制剂的稠合杂环化合物
UY35625A (es) 2013-06-25 2014-12-31 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos como inhibidores de quinasa
CA2916504A1 (en) * 2013-06-25 2014-12-31 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors
MX355943B (es) * 2013-06-26 2018-05-07 Abbvie Inc Carboxamidas primarias como inhibidores de btk.
SG11201601844TA (en) 2013-09-13 2016-04-28 Beigene Ltd Anti-pd1 antibodies and their use as therapeutics and diagnostics
US10662193B2 (en) 2014-01-21 2020-05-26 Ac Immune Sa Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins
CA2948842C (en) 2014-05-15 2019-09-24 Iteos Therapeutics Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors
CN110156892B (zh) 2014-07-03 2023-05-16 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
US10214537B2 (en) 2014-10-22 2019-02-26 Bristol-Myers Squibb Company Bicyclic heteroaryl amine compounds
ES2749679T3 (es) 2014-10-22 2020-03-23 Bristol Myers Squibb Co Compuestos de pirrolotriazina amina sustituidos como inhibidores de PI3k
EP3461821B1 (en) * 2014-10-24 2020-05-13 Bristol-Myers Squibb Company Indole carboxamide compounds useful as kinase inhibitors
SG11201703186RA (en) * 2014-10-24 2017-05-30 Bristol Myers Squibb Co Tricyclic atropisomer compounds
BR112017007545A2 (pt) 2014-10-24 2017-12-19 Bristol Myers Squibb Co derivados de carbazol
CN107205385A (zh) * 2014-12-30 2017-09-26 美国陶氏益农公司 吡啶酰胺作为杀真菌剂的用途
EP3042903B1 (en) 2015-01-06 2019-08-14 Impetis Biosciences Ltd. Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
MX2017011951A (es) 2015-03-17 2018-06-15 Pfizer Derivados sustituidos de indol 3 novedosos, composiciones farmaceuticas y metodos para uso.
WO2016149436A1 (en) * 2015-03-18 2016-09-22 Bristol-Myers Squibb Company Substituted tricyclic heterocyclic compounds
ES2928164T3 (es) 2015-10-19 2022-11-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
WO2017068412A1 (en) * 2015-10-21 2017-04-27 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
CN105272903B (zh) * 2015-11-17 2018-07-10 江苏师范大学 系列含氟咔唑类化合物及其制备方法和应用
HUE060680T2 (hu) 2015-11-19 2023-04-28 Incyte Corp Heterociklusos vegyületek mint immunmodulátorok
JP2017101020A (ja) * 2015-11-25 2017-06-08 宇部興産株式会社 高純度フェノール化合物の製造方法
DK3394033T3 (da) 2015-12-22 2021-01-04 Incyte Corp Heterocykliske forbindelser som immunmodulatorer
MA44860A (fr) 2016-05-06 2019-03-13 Incyte Holdings Corp Composés hétérocycliques utilisés comme immunomodulateurs
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
SG11201811414TA (en) 2016-06-20 2019-01-30 Incyte Corp Heterocyclic compounds as immunomodulators
WO2018007885A1 (en) 2016-07-05 2018-01-11 Beigene, Ltd. COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
ES2930092T3 (es) 2016-07-14 2022-12-07 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
CN110049976A (zh) 2016-07-21 2019-07-23 比奥根Ma公司 布鲁顿氏酪氨酸激酶抑制剂的琥珀酸盐形式和组合物
EA201990519A1 (ru) 2016-08-16 2019-08-30 Бейджин, Лтд. КРИСТАЛЛИЧЕСКАЯ ФОРМА (S)-7-(1-АКРИЛОИЛПИПЕРИДИН-4-ИЛ)-2-(4-ФЕНОКСИФЕНИЛ)-4,5,6,7-ТЕТРАГИДРОПИРАЗОЛО[1,5-a]ПИРИМИДИН-3-КАРБОКСАМИДА, ЕЕ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЯ
AU2017313085B2 (en) 2016-08-19 2024-06-20 Beone Medicines I Gmbh Use of a combination comprising a Btk inhibitor for treating cancers
EP3504198B1 (en) 2016-08-29 2023-01-25 Incyte Corporation Heterocyclic compounds as immunomodulators
MA46285A (fr) 2016-09-19 2019-07-31 Mei Pharma Inc Polythérapie
RS64976B1 (sr) 2016-12-01 2024-01-31 Arvinas Operations Inc Derivati tetrahidronaftalena i tetrahidroizohinolina kao degradatori estrogenih receptora
WO2018118830A1 (en) * 2016-12-20 2018-06-28 Bristol-Myers Squibb Company Process for preparing tetrahydrocarbazole carboxamide compound
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
MD3558990T2 (ro) 2016-12-22 2023-02-28 Incyte Corp Derivați tetrahidro imidazo[4,5-c]piridină ca inductori de internalizare a PD-L1
MA47123A (fr) 2016-12-22 2021-03-17 Incyte Corp Dérivés de benzooxazole en tant qu'mmunomodulateurs
CA3047991A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
TWI774726B (zh) 2017-01-25 2022-08-21 英屬開曼群島商百濟神州有限公司 (S)-7-(1-(丁-2-炔醯基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氫吡唑并[1,5-a]嘧啶-3-甲醯胺的晶型、及其製備和用途
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
TWI877099B (zh) 2017-06-26 2025-03-21 英屬開曼群島商百濟神州有限公司 抗ｐｄ－１抗體或其抗原結合片段在製備治療用於患有肝細胞癌（ｈｃｃ）之藥物的用途
US11377449B2 (en) 2017-08-12 2022-07-05 Beigene, Ltd. BTK inhibitors with improved dual selectivity
US11786529B2 (en) 2017-11-29 2023-10-17 Beigene Switzerland Gmbh Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
US10669271B2 (en) 2018-03-30 2020-06-02 Incyte Corporation Heterocyclic compounds as immunomodulators
LT3790877T (lt) 2018-05-11 2023-05-10 Incyte Corporation Tetrahidro-imidazo[4,5-c]piridino dariniai kaip pd-l1 imunomoduliatoriai
WO2020030754A1 (en) 2018-08-10 2020-02-13 Syngenta Crop Protection Ag Pesticidally-active mesoionic bicyclic heteroaromatic compounds
WO2020035565A1 (en) 2018-08-17 2020-02-20 Syngenta Crop Protection Ag Pesticidally-active mesoionic bicyclic heteroaromatic compounds
TW202045011A (zh) 2019-02-28 2020-12-16 瑞士商先正達農作物保護公司 具有含硫取代基之殺有害生物活性雜環衍生物
EP3981399A4 (en) 2019-06-10 2023-05-31 BeiGene Switzerland GmbH ORAL SOLID TABLET WITH A TYROSINE KINAS INHIBITOR AND METHOD OF MANUFACTURE THEREOF
TW202115059A (zh) 2019-08-09 2021-04-16 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之鹽
CN114667147B (zh) 2019-08-26 2024-09-06 阿尔维纳斯运营股份有限公司 用四氢萘衍生物作为雌激素受体降解剂的治疗乳腺癌的方法
EP4037773A1 (en) 2019-09-30 2022-08-10 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
PE20230407A1 (es) 2019-11-11 2023-03-07 Incyte Corp Sales y formas cristalinas de un inhibidor de pd-1/pd-l1
TW202132300A (zh) 2020-01-06 2021-09-01 瑞士商先正達農作物保護公司 具有含硫取代基的殺有害生物活性雜環衍生物
ES2977339T3 (es) 2020-02-03 2024-08-22 Bristol Myers Squibb Co Compuestos heteroarílicos tricíclicos útiles como inhibidores de IRAK4
US20220009920A1 (en) * 2020-04-10 2022-01-13 Gb005, Inc. Kinase inhibitors
WO2022013417A1 (en) 2020-07-17 2022-01-20 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
WO2022017975A1 (en) 2020-07-18 2022-01-27 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
US20240018128A1 (en) 2020-08-31 2024-01-18 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
UY39401A (es) 2020-09-01 2022-03-31 Syngenta Crop Protection Ag Derivados de isoindolin-1-ona o 7h-pirrolo[3,4-b]piridin-5-ona activos como plaguicidas con sustituyentes que contienen azufre
US20230303565A1 (en) 2020-09-02 2023-09-28 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
CN116234811A (zh) 2020-09-02 2023-06-06 先正达农作物保护股份公司 具有含硫取代基的杀有害生物活性的杂环衍生物
CR20230162A (es) 2020-09-14 2023-06-02 Arvinas Operations Inc Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógenos
AU2021363705A1 (en) * 2020-10-21 2023-06-15 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
WO2022099075A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Crystalline form of a pd-1/pd-l1 inhibitor
WO2022099071A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
WO2023017094A1 (en) 2021-08-10 2023-02-16 Syngenta Crop Protection Ag 2,2-difluoro-5h-[1,3]dioxolo[4,5-f]isoindol-7-one derivatives as pesticides
WO2023187191A1 (en) 2022-04-01 2023-10-05 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder
WO2024033374A1 (en) 2022-08-11 2024-02-15 Syngenta Crop Protection Ag Novel arylcarboxamide or arylthioamide compounds
WO2024089216A1 (en) 2022-10-27 2024-05-02 Syngenta Crop Protection Ag Novel sulfur-containing heteroaryl carboxamide compounds
CN120476107A (zh) 2022-12-15 2025-08-12 先正达农作物保护股份公司 可用作杀有害生物剂的新型的二环-甲酰胺化合物
CN118993985A (zh) * 2023-05-17 2024-11-22 中国医学科学院药物研究所 一种具有抗肿瘤活性的化合物，其制备方法及制药用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001007409A1 (en) 1999-07-23 2001-02-01 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
BR0213208A (pt) 2001-10-09 2004-08-31 Upjohn Co Compostos de tetraidro- e hexaidro-carbazóis de arilsulfonila substituìda, suas composições e usos
ATE427308T1 (de) 2003-04-11 2009-04-15 Glenmark Pharmaceuticals Sa Neue heterozyklische verbindungen, die sich fur die behandlung von entzundlichen und allergischen erkrankungen eignen: verfahren zu deren herstellung und pharmazeutische zusammensetzungen,die diese enthalten
US20060183746A1 (en) 2003-06-04 2006-08-17 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
WO2005005429A1 (en) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
US20050288295A1 (en) 2003-11-11 2005-12-29 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
WO2005099656A2 (en) 2004-04-06 2005-10-27 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
PE20060748A1 (es) * 2004-09-21 2006-10-01 Smithkline Beecham Corp Derivados de indolcarboxamida como inhibidores de quinasa ikk2
CN101035528A (zh) 2004-09-23 2007-09-12 惠氏公司 治疗丙型肝炎病毒感染的咔唑和环戊二烯并吲哚衍生物
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
NZ555681A (en) 2004-11-10 2009-08-28 Cgi Pharmaceuticals Inc Imidazo[1, 2-a] pyrazin-8-ylamines useful as modulators of kinase activity
US20060173183A1 (en) 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
WO2006099075A2 (en) 2005-03-10 2006-09-21 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
AU2006316605B2 (en) 2005-11-17 2012-04-26 Osi Pharmaceuticals, Inc. Fused bicyclic mTOR inhibitors
WO2007061764A2 (en) 2005-11-22 2007-05-31 Merck & Co., Inc. Tricyclic compounds useful as inhibitors of kinases
WO2008021851A2 (en) 2006-08-09 2008-02-21 Smithkline Beecham Corporation Novel compounds as antagonists or inverse agonists for opioid receptors
WO2008021745A2 (en) 2006-08-16 2008-02-21 Itherx Pharmaceuticals, Inc. Hepatitis c virus entry inhibitors
US20100160292A1 (en) 2006-09-11 2010-06-24 Cgi Pharmaceuticals, Inc Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors
RU2009113585A (ru) 2006-09-11 2010-10-20 Матрикс Лэборетериз Лтд. (In) Производные дибензофурана в качестве ингибиторов pde-4 и pde-10
US7492329B2 (en) 2006-10-12 2009-02-17 Hewlett-Packard Development Company, L.P. Composite material with chirped resonant cells
WO2008057254A2 (en) 2006-10-27 2008-05-15 Wyeth Tricyclic compounds as matrix metalloproteinase inhibitors
WO2008064317A1 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Lipophilic opioid receptor active compounds
WO2008064318A2 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Peripheral opioid receptor active compounds
EP2121692B1 (en) 2006-12-22 2013-04-10 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
SE530889C2 (sv) 2007-02-27 2008-10-07 Scania Cv Abp Bränsletankarrangemang för ett fordon
DE102007056922A1 (de) 2007-11-27 2009-05-28 BSH Bosch und Siemens Hausgeräte GmbH Wasserführendes Hausgerät mit einer Wasserweiche
AU2008335761B2 (en) 2007-12-13 2014-04-24 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
JP5381718B2 (ja) 2008-01-31 2014-01-08 コニカミノルタ株式会社 ハロ多環芳香族化合物及びその製造方法
EP2095818A1 (en) 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
JP5487214B2 (ja) * 2008-12-19 2014-05-07 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ阻害剤として有用なカルバゾールカルボキシアミド化合物
US8815840B2 (en) 2008-12-19 2014-08-26 Bristol-Myers Squibb Company Carbazole and carboline kinase inhibitors

Also Published As

Publication number Publication date
US8084620B2 (en) 2011-12-27
EA201100992A1 (ru) 2011-12-30
WO2010080481A1 (en) 2010-07-15
TW201028401A (en) 2010-08-01
SG171815A1 (en) 2011-07-28
JP5487214B2 (ja) 2014-05-07
CL2011001516A1 (es) 2012-01-20
JP2012512888A (ja) 2012-06-07
EP2391602A1 (en) 2011-12-07
MX2011006171A (es) 2011-06-20
BRPI0922565A2 (pt) 2015-12-15
NZ593096A (en) 2012-11-30
PE20110819A1 (es) 2011-11-02
KR20110098827A (ko) 2011-09-01
CN102325753B (zh) 2014-09-10
US20100160303A1 (en) 2010-06-24
CA2747670A1 (en) 2010-07-15
US8362065B2 (en) 2013-01-29
IL213185A0 (en) 2011-07-31
TN2011000274A1 (en) 2012-12-17
EP2391602B1 (en) 2013-12-04
US20120058996A1 (en) 2012-03-08
EA019041B1 (ru) 2013-12-30
CO6390055A2 (es) 2012-02-29
AR074812A1 (es) 2011-02-16
AU2009335821A1 (en) 2010-07-15
CN102325753A (zh) 2012-01-18
ES2443948T3 (es) 2014-02-21

Similar Documents

Publication Publication Date Title
IL213185A0 (en) Carbazole carboxamide compounds useful as kinase inhibitors
ZA201102423B (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
ZA201008808B (en) Novel phenylpyrazinones as kinase inhibitors
ZA201004942B (en) Ptrrolopyrazine kinase inhibitors
IL218271A0 (en) Heterocyclic compounds as janus kinase inhibitors
ZA201101118B (en) Picolinamide derivatives as kinase inhibitors
IL210573A0 (en) Compounds as kinase inhibitors
IL213464A0 (en) Kinase inhibitor compounds
ZA200908624B (en) 5-heteroaryl substituted indazoles as kinase inhibitors
IL219385A0 (en) N-containing heteroayl derivatives as kaj3 kinase inhibitors
PL3354650T3 (pl) Związki przydatne jako inhibitory kinazy atr
ZA201103411B (en) Compounds useful as inhibitors of atr kinase
IL210124A0 (en) Pyrimidine derivatives as kinase inhibitors
IL194424A0 (en) 4-anilinoquinoline-3-carboxamides as csf-1r kinase inhibitors
IL206394A0 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
IL208136A0 (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases
EP2336123A4 (en) HETEROCYCLIC COMPOUND AS INHIBITOR OF PROTEIN KINASE
IL210099A0 (en) Substituted pyridazine carboxamide compounds as kinase inhibitor compounds
IL220205A0 (en) Heterocyclic compounds as janus kinase inhibitors
ZA201008878B (en) Naphthyridiniones as aurora kinase inhibitors
HK1159082A (en) Carbazole carboxamide compounds useful as kinase inhibitors